Merck has entered into a definitive agreement to acquire Cubist Pharmaceuticals, Inc. in a transaction valued at approximately $9.5 billion. Cubist develops and supplies antibiotics to treat serious and potentially life-threatening infections caused by a broad range of increasingly drug-resistant bacteria.   Cubist’s antibiotic CUBICIN is the only approved once-a-day therapy for both S. aureus bacteremia and complicated skin and skin structure infections (cSSSI). Cubist has a late-stage pipeline...